Healthcare firm Alembic Pharma's fourth quarter (January-March) net profit grew 115 percent year-on-year to Rs 43.6 crore, sending shares to 52-week high of Rs 122 on Thursday.
Consolidated net sales rose by 10 percent to Rs 376.6 crore from Rs 342.3 crore Y-o-Y.
Its domestic formulations' sales jumped 12 percent Y-o-Y to Rs 207.52 crore while international generics sales grew by 54 percent to Rs 77.66 crore.
Also Read - Aurobindo Pharma receives USFDA nod for Quinapril tablets
In the three-month period, the company launched Desvenlafaxine Base extended release tablets in the US. Company also made its new formulations facility partially operational during the quarter.
At 14:55 hours IST, the stock gained 1.88 percent to Rs 116.30 amid hefty volumes on Bombay Stock Exchange.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
